LIBTAYO(Lebrikizumab) Instructions:Uses,Dosage, Side Effects

LIBTAYO (cemiplimab-rwlc) is a monoclonal antibody that works as a programmed cell death protein-1 (PD-1) inhibitor. It is primarily used for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) in patients who are not candidates for curative surgery or radiation. By blocking the PD-1 receptor, LIBTAYO enhances the immune system's ability to target and destroy cancer cells, offering an important treatment option for advanced cases of CSCC.

The recommended dosage of LIBTAYO is 350 mg administered intravenously every 3 weeks. It can be continued until disease progression or intolerable side effects occur. While effective, LIBTAYO may cause immune-mediated reactions, infusion-related reactions, and fetal harm, which necessitate careful monitoring during treatment.